Cencora, Inc. (COR)
- Previous Close
239.13 - Open
236.00 - Bid --
- Ask --
- Day's Range
234.73 - 239.01 - 52 Week Range
163.37 - 246.75 - Volume
2,263,041 - Avg. Volume
1,261,170 - Market Cap (intraday)
47.197B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
25.77 - EPS (TTM)
9.19 - Earnings Date May 1, 2024
- Forward Dividend & Yield 2.04 (0.86%)
- Ex-Dividend Date Feb 8, 2024
- 1y Target Est
254.50
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
www.cencora.com42,000
Full Time Employees
September 30
Fiscal Year Ends
Sector
Industry
Recent News: COR
Performance Overview: COR
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COR
Valuation Measures
Market Cap
47.20B
Enterprise Value
49.10B
Trailing P/E
25.80
Forward P/E
17.76
PEG Ratio (5yr expected)
2.65
Price/Sales (ttm)
0.18
Price/Book (mrq)
51.77
Enterprise Value/Revenue
0.18
Enterprise Value/EBITDA
13.24
Financial Highlights
Profitability and Income Statement
Profit Margin
0.69%
Return on Assets (ttm)
2.72%
Return on Equity (ttm)
327.70%
Revenue (ttm)
271.58B
Net Income Avi to Common (ttm)
1.87B
Diluted EPS (ttm)
9.19
Balance Sheet and Cash Flow
Total Cash (mrq)
2.87B
Total Debt/Equity (mrq)
582.06%
Levered Free Cash Flow (ttm)
5.72B
Research Analysis: COR
Company Insights: COR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: COR
Analyst Report: Cencora Inc
Headquartered in Conshohocken, Pennsylvania, Cencora, formerly AmerisourceBergen, is one of the nation's largest pharmaceutical distributors. The company distributes brand-name and generic pharmaceuticals, over-the-counter (OTC) healthcare products, and home healthcare supplies and equipment to healthcare providers throughout the U.S. It also provides pharmaceuticals and pharmacy services to patients requiring specialty drugs such as immunology and oncology treatments. Cencora has international operations through its World Courier logistics business and assets acquired from Alliance Healthcare and PharmaLex.
RatingPrice TargetMarket Digest: COR, CMG
Solid 1Q Leads into 2Q Uncertainty
Technical Assessment: Neutral in the Intermediate-Term
We are one session away from making it 17 out of 19 weeks in which stocks have moved to the upside. We've been throwing grenades at this move for a while, based on overbought and divergent momentum readings and excessive sentiment readings -- and it just does not matter. Yes, price is the final arbiter!
Weekly Stock List
Management's ability to "raise guidance" can often be a catalyst for market-beating returns in the quarters ahead. The fourth-quarter earnings season has crossed the 95% mark and is wrapping up, with blended earnings (actual results and the consensus for those still to report) showing a year-over-year gain of almost 10%, according to Refinitiv. That is considerably better than the 4%-7% advance expected at the start of the earnings period. Leading the outperformance were strong gains in Communication Services earnings, up 53%. On the flipside, Energy (like last quarter) is performing the worst, down 22%. Our analysts are always on the lookout for companies that boost their outlooks during earnings season. Here is an initial list of BUY-rated companies in Argus' Fundamental Universe of Coverage at which management raised guidance or increased its outlook during the 4Q23 EPS reporting season.